INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
View HTML
Toggle Summary Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
Robust balance sheet to support global expansion of ACH-4471 clinical development program in PNH and C3G
View HTML
Toggle Summary USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to Achillion for ACH-4471. U.S. Patent No. 9,796,741, entitled "Aryl, Heteroaryl, and Heterocyclic Compounds
View HTML
Toggle Summary Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
- 98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6 -
View HTML
Toggle Summary Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series
NEW HAVEN, Conn., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will provide a corporate update at the 2017 Leerink Partners Rare Disease Roundtable Series on Wednesday, September 27, 2017 at 10:00 a.m.
View HTML
Toggle Summary Achillion Announces Strengthening of Management Team
- Mr. Joseph Truitt promoted to Chief Operating Officer -  - Dr. Avner Ingerman joins as Head of Ophthalmology - NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Executive Vice President Joseph Truitt has been promoted to Chief
View HTML
Toggle Summary Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen
- Conference call to be held today at 9:00 a.m. ET- NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that on Saturday, September 9, 2017, it received notice of termination of the worldwide license and collaboration arrangement on
View HTML
Toggle Summary Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN - - Conference call scheduled for today at 4:05 p.m. ET - NEW HAVEN, Conn., Aug.
View HTML
Toggle Summary Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017
- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -
View HTML
Toggle Summary Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change
NEW HAVEN, Conn., July 10, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), the leader in complement alternative pathway therapeutics, today announced that Mingjun Huang, Ph.D., is being promoted to Senior Vice President and Head of Research. With this promotion, Dr.
View HTML